Anúncio
Anúncio

RVPH

RVPH logo

Reviva Pharmaceuticals Holdings, Inc. Common Stock

0.38
USD
Patrocinado
+0.01
+2.46%
09 de jan., 12:55 UTC -5
Abrir

Relatórios de Lucros RVPH

Rácio de surpresa positiva

RVPH separação 13 de 18 últimas estimativas.

72%

Próximo Relatório

Data do Próximo Relatório
30 de mar. de 2026
Estimate for Q4 25 (Revenue/ EPS)
--
/
-$0.08
Mudanças implicadas de Q3 25 (Revenue/ EPS)
--
/
+33.33%
Mudanças implicadas de Q4 24 (Revenue/ EPS)
--
/
-46.67%

Reviva Pharmaceuticals Holdings, Inc. Common Stock earnings per share and revenue

On 13 de nov. de 2025, RVPH reported earnings of -0.06 USD per share (EPS) for Q3 25, beating the estimate of -0.09 USD, resulting in a 39.46% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a -7.19% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 10 analistas forecast an EPS of -0.08 USD, with revenue projected to reach -- USD, implying an aumentar of 33.33% EPS, and aumentar of 0.00% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
Citius Pharmaceuticals Inc. Common
Report Date
26 de dez. de 2025 Para Q4 25
Estimativa
-$0.49
Real
-
Surpresa
-
FAQ
For Q3 2025, Reviva Pharmaceuticals Holdings, Inc. Common Stock reported EPS of -$0.06, beating estimates by 39.46%, and revenue of $0.00, 0% as expectations.
The stock price moved down -7.19%, changed from $0.54 before the earnings release to $0.50 the day after.
The next earning report is scheduled for 30 de mar. de 2026.
Based on 10 analistas, Reviva Pharmaceuticals Holdings, Inc. Common Stock is expected to report EPS of -$0.08 and revenue of -- for Q4 2025.
Verificar FXEmpire's Earnings Calendar for today's list of reporting companies.
Anúncio